Immix Biopharma, Inc.

Listed Company

IMMXCIK 0001873835NasdaqEmerging GrowthPharmaceutical PreparationsDelawareFY ends Dec 31

Period

FY 2025

Revenue

—

Net Income

$-29.40M

Total Assets

$104.84M

Equity

$93.80M

Shares Out

52.96M

Op. Cash Flow

$-23.93M

Business

Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on developing chimeric antigen receptor T‑cell (CAR‑T) therapies for light‑chain (AL) amyloidosis and select immune‑mediated diseases. Its main product candidates include NXC‑201, a next‑generation BCMA‑targeting autologous CAR‑T, along with additional preclinical cell therapy programs and platform‑derived assets. The company operates as a single business segment centered on its N‑GENIUS cell engineering platform (including EXPAND and COBRA technologies) and its lead clinical program NEXICART trials. It conducts clinical development and manufacturing through U.S. and ex‑U.S. clinical sites and relies on third‑party contract manufacturers and global regulatory pathways for distribution and commercialization.

Summary from filing dated 2025-03-25

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
General and administrative expenses	14	11	7	4	1
Research and development	16	11	9	4	126,527
Total operating expenses	30	23	16	8	1
Loss from operations	−30	−23	−16	−8	−1
Interest income	555,526	1	572,006	—	—
Total other income	555,526	1	572,006	−497	−23
Loss before provision for income taxes	−29	−22	−16	−8	−24
Provision for income taxes	37,724	41,037	26,415	10,268	6,013
Net loss	−29	−22	−16	−8	−24
Net loss attributable to non-controlling interests	—	84,987	169,474	—	—
Net loss attributable to Immix Biopharma, Inc. common stockholders	−29	−22	−15	−8	−24
Foreign currency translation	61,216	−135,722	47,645	−38,387	−6,453
Total other comprehensive income (loss)	61,216	−135,722	47,645	−38,387	−6,453
Comprehensive loss	−29	−22	−15	—	—
Loss per common share - basic	−0.89	−0.76	−0.89	−0.59	−6.64
Loss per common share - diluted	−0.89	−0.76	−0.89	−0.59	—
Weighted average shares outstanding - basic	33	28	17	14	4
Weighted average shares outstanding - diluted	33	28	17	14	—

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	94	18	18	13	18
Short-term investments	7	—	—	—	—
Tax receivable	—	2	1	255,705	25,722
Prepaid expenses and other current assets	828,329	541,510	1	1	516,193
Total current assets	101	20	20	15	18
Other assets	20,418	20,418	—	6,724	—
Deferred offering costs	93,630	—	87,229	6,724	—
Right-of-use asset, net	966,917	989,471	—	—	—
Property and equipment, net	3	2	50,181	3,560	5,695
Total assets	105	23	20	15	18
Accounts payable and accrued expenses	10	9	4	1	142,940
Operating lease liabilities - current	139,339	65,219	—	—	—
Total current liabilities	10	9	4	1	202,039
Operating lease liabilities - long term	933,625	1	—	—	—
Total liabilities	11	10	4	2	202,039
Preferred stock, $0.0001 par value; 10,000,000 shares authorized; no shares issued and outstanding	—	—	—	—	—
Common stock, $0.0001 par value; 200,000,000 shares authorized; 53,023,466 shares issued and 52,951,103 shares outstanding at December 31, 2025, and 27,612,383 shares issued and 27,540,020 shares outstanding at December 31, 2024	5,301	2,762	2,000	1,397	1,323
Additional paid-in capital	198	88	70	51	48
Accumulated other comprehensive income	60,160	−1,056	134,666	87,021	125,408
Accumulated deficit	−105	−75	−53	−38	−30
Treasury stock at cost, 72,363 shares as of December 31, 2025, and 2024	−99,963	−99,963	—	—	—
Total stockholders equity	94	13	16	13	18
Total liabilities and stockholders equity	105	23	20	15	18

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Stock-based compensation	2	3	3	624,069	218,983
Depreciation	245,747	32,941	5,468	2,135	2,468
Amortization of right of use asset	118,754	82,447	—	—	—
Tax receivable	2	−971,527	−893,401	−236,384	97,667
Prepaid expenses and other current assets	−286,729	554,770	111,842	−691,047	−502,795
Other assets	—	−20,418	—	—	—
Accounts payable and accrued expenses	1	4	2	—	—
Operating lease liability	−98,006	2,852	—	—	—
Net cash used in operating activities	−24	−15	−11	−7	−2
Purchase of property and equipment	−732,925	−1	−52,089	—	−802
Purchase of short-term investments	−6	—	—	—	—
Net cash used in investing activities	−7	−1	−52,089	—	−802
Payments of deferred offering costs	−136,999	—	−234,616	−6,724	—
Proceeds from exercise of stock options	6,342	2,489	2,618	—	—
Proceeds from exercise of stock warrants	124,800	—	—	—	—
Proceeds from sale of common stock, net of offering costs	107	16	16	3	19
Net cash provided by financing activities	107	16	15	3	19
Effect of foreign currency on cash	3,842	−3,622	33,092	−31,524	−5,433
Net change in cash and cash equivalents	76	172,163	4	−4	17
Interest paid	—	—	—	9,596	1,542
Income taxes paid	—	—	—	—	—
Establishment of right of use asset and liabilities	96,200	1	—	—	—
Purchases of property and equipment included in accounts payable and accrued liabilities	294,294	545,229	—	—	—
Deferred offering costs charged against proceeds from sale of common stock	43,369	87,229	147,387	—	—
Shares issues in subsidiary absorption	—	99	—	—	—
Shares issued for vested RSUs	26	—	—	—	28

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro